Saturday, November 23, 2024

Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001

Valneva SE a specialty vaccine company, announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001. This is the second purchase agreement Valneva has secured for VLA2001 since reporting positive data for its Phase 3 clinical trial Cov-Compare.

Also Read: Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant

Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority (NHRA).

Franck Grimaud, Chief Business Officer of Valneva, commented, “We are grateful to the Bahraini government for their trust and confidence in our vaccine and are eager to work with them to start helping to address the pandemic evolution in the Middle-East. Subject to regulatory review and approval, we plan to start deliveries in the first quarter of 2022.”

A Bahraini government spokesperson stated, “Bahrain is once again at the forefront on adopting new measures to protect the health of citizens and residents against the threat of COVID-19. Subject to approval, Bahraini citizens and residents will have the ability to choose from a variety of vaccines in Bahrain that will have a positive impact on driving up vaccinations rates with 93% of the eligible population now fully vaccinated in the Kingdom.”

Last month, Valneva announced that the European Commission signed an advanced purchase agreement for up to 60 million doses of VLA20011. Valneva reported positive Phase 3 results for VLA2001 in October 20212.

About VLA2001
VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva established Vero-cell platform,

Subscribe Now

    Hot Topics